p53 expression in tumor-stromal fibroblasts is closely associated with the nodal metastasis and outcome of patients with invasive ductal carcinoma who received neoadjuvant therapy

Grading system for lymph vessel tumor emboli: significant outcome predictor for patients with invasive ductal carcinoma of the breast who received neoadjuvant therapy

“…The Allred scores for p53 in lymph vessel tumor emboli assessed in the surgical specimens were significantly associated with the grades of the lymph vessel tumor emboli assessed in the surgical specimens (Table 1), but there were no significant associations between the Allred scores for estrogen receptor or progesterone receptor in lymph vessel tumor emboli, or the HER2 categories in the lymph vessel tumor emboli and grades of lymph vessel tumor embolus assessed in the surgical specimens (data not shown). In our previous study, although the multivariate analysis clearly showed that negative nodal status and HER2 category 3 in tumor cells were significantly associated with pathological complete response, 8 the lymph vessel tumor embolus grades based on the biopsy specimens were not significantly associated with pathological complete response in the univariate analysis (data not shown).…”

“…The subjects of this study were the 318 consecutive patients with IDC of the breast who received neoadjuvant therapy and were surgically treated at the National Cancer Center Hospital between January 2000 and December 2005 (the same series of patients as in an earlier study we conducted 8 and 88 patients of the 318 patients in this series were included among the subjects of our previous study 7 ). Their IDCs were diagnosed preoperatively by needle biopsy, aspiration cytology, mammography, or ultrasonography.…”

“…8,[18][19][20][21][22] The highest intensity score, not the average intensity score, for nuclear expression of p53 was assigned for in tumor-stromal fibroblasts, and the highest p53 nuclear expression proportion score and intensity score were then to be evaluated in one high-power field (  40 objective and  10 ocular). 8 The Allred scores for estrogen receptor, progesterone receptor, and p53 expression in stroma-invasive tumor cells and tumor-stromal fibroblasts were classified into the following three categories: (1) Allred score for estrogen receptor in stroma-invasive tumor cells, 0 or 2, 3-6, and 7 or 8; (2) Allred score for progesterone receptor in stromainvasive tumor cells, 0 or 2, 3-6, and 7 or 8; (3) Allred scores for p53 in stroma-invasive tumor cells, 0 or 2 or 3, 4-6, and 7 or 8; and (4) Allred scores for p53 in tumor-stromal fibroblasts, 0 or 2, 3, and 4-8. HER2 expression in stroma-invasive tumor cells was classified into the three categories: 0 or 1, 2, and 3.…”

“…7 The purpose of this study was to confirm that the grading system for lymph vessel tumor embolus is a significant outcome predictor for IDC patients who received neoadjuvant therapy according to nodal status, by multivariate analysis with well-known clinicopathological factors and p53 protein expression in tumor-stromal fibroblasts in IDCs. 8 p53 protein expression in tumor-stromal fibroblasts, but not in tumor cells, in IDCs has been recently demonstrated to be a very important outcome predictor for IDC patients who received neoadjuvant therapy. 8 The results of this study clearly showed that the grading system for lymph vessel tumor emboli is an excellent histological outcome predictive of the histological grading system for IDC patients who received neoadjuvant therapy independent of nodal metastasis.…”

“…8 p53 protein expression in tumor-stromal fibroblasts, but not in tumor cells, in IDCs has been recently demonstrated to be a very important outcome predictor for IDC patients who received neoadjuvant therapy. 8 The results of this study clearly showed that the grading system for lymph vessel tumor emboli is an excellent histological outcome predictive of the histological grading system for IDC patients who received neoadjuvant therapy independent of nodal metastasis.…”